Knight Therapeutics Inc. (TSX:GUD)

Market Cap	628.88M +11.8%
Revenue (ttm)	413.85M +18.7%
Net Income	-3.49M
EPS	-0.04
Shares Out	99.19M
PE Ratio	n/a
Forward PE	202.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,922
Average Volume	157,370
Open	6.23
Previous Close	6.28
Day's Range	6.22 - 6.37
52-Week Range	5.42 - 6.57
Beta	0.13
RSI	57.97
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD